December 1, 2020 7:56am

And vaccine news

Pre-open indications: 1 BUY and 7 SELLs

News: REGENXBIO (RGNX) announced that the first patient has been dosed in the P1/2 trial of RGX-111 for the treatment of Mucopolysaccharidosis Type I (MPS I). RGX-111 is an investigational one-time gene therapy designed to deliver the α-l-iduronidase (IDUA) gene directly to the central nervous system (CNS) using the NAV AAV9 vector.

What I provide is an “intelligence daily” to ensure that shareholders are kept apprised based on a 24-hour surveillance of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

 

 

Dow futures are UP +1.05% (+310 points), S&P futures are UP +0.98% (+36 points) and NASDAQ futures are UP +0.87% (+107 points)

 

U.S. stock futures jumped on Tuesday;

European stocks traded in positive territory as the pan-European Stoxx 600 gained +0.9% by late morning;

Asia-Pacific were higher on Tuesday as investors reacted to the release of a private survey and MSCI’s index of Asia-Pacific shares outside Japan rose +1.26%

 

Data Docket: Meanwhile in the Asia-Pacific markets, shares were higher in Tuesday trade as investors reacted to the release of a private survey of China’s manufacturing activity. The Caixin/Markit manufacturing Purchasing Managers’ Index for November came in at 54.9 — its highest reading in a decade. PMI readings above 50 signify expansion, while those below that level represent contraction.

 

Henry’omics:

There is a question of the follow-on after a November rally as ...

The Dow rallied 11.8% in November, posting its best one-month performance since January 1987. The S&P 500 rose 10.8%n and the Nasdaq 11.8%, also for their strongest monthly advances since April.

 

An Update: RegMed/Cell and Gene Therapy Earnings Scorecard Q3/20 LPS Results https://www.regmedinvestors.com/articles/11628     

 

Intellia Therapeutics (NTLA) proposes offering … https://www.regmedinvestors.com/articles/11655

 

Monday’s night’s recap: RegMed Investors’ (RMi) closing bell: “indexes dip, sector goes out with a whimper and a positive close. Optimism gets rebalanced; while vaccines are not yet arm-ready vial filled … https://www.regmedinvestors.com/articles/11656

  • The Nasdaq closed DOWN -7.11 points (-0.06%);
  • The IBB closed up +0.35 % and XBI closed up +0.27%;
  • Sector volume was the usual LOW with 12 of the 21-upside having higher than the 3-month average volume with the increased volume of 9 of 13-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -0.27 points or -1.30% at 20.57;
  • Monday’s percentage (%) of the 21-upside were +0.04% (ALNY) to +15.67% (BCLM) while the 13- downside of -0.14% (KDNY) to -5.96% (RGNX);

Q4’s: December 1st

  • Q4’s November, so far: 16 positive and 3 negative closes
  • Q4’s October: 1 neutral, 11 positives with 1 negative closes
  • Q3: July through September: 1 neutral, 28 positive and 34 negative closes with 2 holidays

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed down -$0.01 to $1.35 with 1,575 shares traded after Friday’s -0.04 to $1.36 with 1,200 shares traded following Thursday’s holiday after Wednesday’s flat with 900 shares traded and last Tuesday’s flat at $1.40 with 1,200 shares traded).

  • Question#1: As one watches the trading of BSTG’s stock; WHO and WHICH firm is BUYING i.e. PUMPING the stock?

SELL into Strength:

Fate Therapeutics (FATE) closed up again +$0.55 to $58.47 after Friday’s +$0.79 to $57.92, Thursday’s holiday, Wednesday’s +$1.86 to $57.13 and last Tuesday’s +$0.98 to $55.27 with a POSITIVE +$0.78 or +1.34% aftermarket indication. A 52-week change of +308.46% and a short percentage (%) of float of -22.79%, There’s “room” to profit;

Pluristem (PSTI) closed up +$0.53 to $10.11, after Friday’s +$9.58, Thursday’s holiday, Wednesday’s +$9.31 and last Tuesday’s +$9.14 with NO aftermarket indication

 

Maintain SELL into any Strength:

Verastem Oncology (VSTM) closed up +$0.02 to $2.01 after Friday’s +$0.29 to $1.99 and has a NEGATIVE -0.01 or -0.50% aftermarket indication following news

Mesoblast (MESO) closed up +$0.16 to $15.09 after Friday’s +$14.93, Thursday’s holiday, Wednesday’s $16.74 and last Tuesday’s $15.81 and has a NEGATIVE -$0.08 or -0.53% aftermarket indication;

 

SELL:

Intellia Therapeutics (NTLA) closed down -$0.11 to $39.27 after news of a proposed offering of $150 million and has a NEGATIVE -$0.08 or -0.53% aftermarket indication;

Global Blood Therapeutics (GBT) closed up +$1.01 to $45.91 after Friday’s +$44.90, Thursday’s holiday, Wednesday’s $43.85 and last Tuesday’s $43.57 and has a NEGATIVE -$0.46 or -1% aftermarket indication;

 

BUY:

Ionis Pharmaceuticals (IONS) closed down -$0.60 to $50.53 after Friday’s +$51.13, Thursday’s holiday, Wednesday’s $50.24 and last Tuesday’s $50.04 and has a POSITIVE +$0.23 or +0.46% aftermarket indication;

 

The BOTTOM LINE: I am getting nervous after November’s highs as the Dow rallied 11.8%, the S&P 500 at +10.8% and Nasdaq +11.8%. Thus, I formulate Selling into Strength partial or some positions.

November’s rally also came amid a slew of positive coronavirus vaccine news, which lifted hope of a strong economic recovery and sparked a surge in beaten-down value names ...but, when will the vaccines be needle filled and arm swabbed?

Data compiled by Johns Hopkins University shows that more than 13 million Covid-19 cases have been confirmed in the U.S. along with over 266,000 deaths. In New York, Gov. Andrew Cuomo said the state was implementing emergency hospital measures as cases continue to rise. Meanwhile, Federal Reserve Chairman Powell called the U.S. economic outlook “extraordinarily uncertain.” <CNBC>

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.